Comparative Pharmacology
Head-to-head clinical analysis: ANCEF versus CEFOBID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANCEF versus CEFOBID.
ANCEF vs CEFOBID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
First-generation cephalosporin that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking.
Cefoperazone is a third-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby inhibiting peptidoglycan cross-linking and causing cell lysis.
1-2 g IV/IM every 8 hours; maximum 6 g/day.
2-4 g/day IV/IM divided q12h; severe infections: 6-12 g/day IV divided q8-12h
None Documented
None Documented
1.5-2 hours in adults with normal renal function; prolongs significantly in renal impairment (up to 30 hours in anuria).
2 hours (prolonged in hepatic impairment and neonates).
Primarily renal (80-90% unchanged by glomerular filtration and tubular secretion); small amounts biliary (<1%) and fecal.
Primarily renal (80-90% unchanged in urine) and biliary (10-20%).
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic